Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-Time glucose monitor may help type 2 diabetes patients without insulin

NCT ID NCT07298850

Symptom relief Sponsor: Kangbuk Samsung Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether wearing a continuous glucose monitor (CGM) and seeing real-time blood sugar readings can help people with type 2 diabetes who don't use insulin improve their glucose control. For one week, participants wear the device without seeing their numbers; the next week, they see their levels and trends. Researchers compare the time spent in a healthy blood sugar range between the two weeks to see if just having the information makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitoring (CGM) device
What this could lead to
If it works, this could show that simply viewing real-time glucose readings helps people with type 2 diabetes better manage their blood sugar without needing extra training or medication changes.
What could go wrong
This is a small, early-stage study with only 120 participants and a short two-week monitoring period. The results may not apply to all people with type 2 diabetes, and the improvement might be small or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with Type 2 Diabetes Mellitus (HbA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL during 75g OGTT, or random plasma glucose ≥ 200 mg/dL with classic symptoms) 2. No medication changes in the past 3 months, and receiving treatment with lifestyle modification or oral antidiabetic drugs or GLP-1 receptor agonists 3. Ages 19 - 80 years old 4. Patients who have voluntarily signed the informed consent form Exclusion Criteria: 1. Type 1 diabetes patients 2. Insulin users 3. Patients who have changed oral hypoglycemic agents within the past 3 months 4. Patients scheduled for hospitalization within 2 weeks 5. Pregnant women or those planning pregnancy within 1 month 6. Those who do not agree to the program 7. Those deemed unsuitable for participation in this clinical trial by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Type 2 diabetes

Contacts and locations

Locations

  • Kangbuk Samsung Hospital

    Seoul, Jongro-Ku, 03181, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.